These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38404266)

  • 1. [New perspective of anticoagulation in intensive care unit: basic and clinical advances in coagulation factor XII and XI inhibitors].
    Wang R; Yang Z; Ma S; Zhu F
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 Jan; 36(1):16-22. PubMed ID: 38404266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rebirth of the contact pathway: a new therapeutic target.
    Srivastava P; Gailani D
    Curr Opin Hematol; 2020 Sep; 27(5):311-319. PubMed ID: 32740037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials.
    DeLoughery EP; Olson SR; Puy C; McCarty OJT; Shatzel JJ
    Semin Thromb Hemost; 2019 Jul; 45(5):502-508. PubMed ID: 31216587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hemostatic role of factor XI.
    Puy C; Rigg RA; McCarty OJ
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S8-S11. PubMed ID: 27207433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation factors XI and XII as possible targets for anticoagulant therapy.
    Kluge KE; Seljeflot I; Arnesen H; Jensen T; Halvorsen S; Helseth R
    Thromb Res; 2022 Jun; 214():53-62. PubMed ID: 35490644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation.
    Stroo I; Zeerleder S; Ding C; Luken BM; Roelofs JJTH; de Boer OJ; Meijers JCM; Castellino FJ; van 't Veer C; van der Poll T
    Thromb Haemost; 2017 Jul; 117(8):1601-1614. PubMed ID: 28492700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of blood coagulation factors XI and XII in patients with acute and chronic cerebrovascular disease: a case-control study.
    Kraft P; Drechsler C; Gunreben I; Heuschmann PU; Kleinschnitz C
    Cerebrovasc Dis; 2014; 38(5):337-43. PubMed ID: 25427539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
    Vlădăreanu AM; Roşca A
    Rom J Intern Med; 2024 Jun; 62(2):91-100. PubMed ID: 38153875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism.
    Cohen O; Ageno W
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):495-505. PubMed ID: 36485148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor XI and XII as antithrombotic targets.
    Müller F; Gailani D; Renné T
    Curr Opin Hematol; 2011 Sep; 18(5):349-55. PubMed ID: 21730835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor XI and contact activation as targets for antithrombotic therapy.
    Gailani D; Bane CE; Gruber A
    J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The many faces of the contact pathway and their role in thrombosis.
    Woodruff RS; Sullenger B; Becker RC
    J Thromb Thrombolysis; 2011 Jul; 32(1):9-20. PubMed ID: 21404067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flow.
    Keeling NM; Wallisch M; Johnson J; Le HH; Vu HH; Jordan KR; Puy C; Tucker EI; Nguyen KP; McCarty OJT; Aslan JE; Hinds MT; Anderson DEJ
    J Thromb Haemost; 2024 May; 22(5):1433-1446. PubMed ID: 38331196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor XI and factor XII as targets for new anticoagulants.
    Weitz JI
    Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis.
    Govers-Riemslag JWP; Konings J; Cosemans JMEM; van Geffen JP; de Laat B; Heemskerk JWM; Dargaud Y; Ten Cate H
    TH Open; 2019 Jul; 3(3):e273-e285. PubMed ID: 31511847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.
    Woodruff RS; Xu Y; Layzer J; Wu W; Ogletree ML; Sullenger BA
    J Thromb Haemost; 2013 Jul; 11(7):1364-73. PubMed ID: 23692437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immobilized transition metal ions stimulate contact activation and drive factor XII-mediated coagulation.
    Mutch NJ; Waters EK; Morrissey JH
    J Thromb Haemost; 2012 Oct; 10(10):2108-15. PubMed ID: 22905925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor XI contributes to thrombin generation in the absence of factor XII.
    Kravtsov DV; Matafonov A; Tucker EI; Sun MF; Walsh PN; Gruber A; Gailani D
    Blood; 2009 Jul; 114(2):452-8. PubMed ID: 19351955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiologic and clinical data linking factors XI and XII to thrombosis.
    Key NS
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):66-70. PubMed ID: 25696836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.
    Chan NC; Weitz JI
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):1755-1763. PubMed ID: 37650326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.